ArticleCurrent medical science2026
Mitofusin 2 Alleviates Liver Fibrogenesis by Suppressing β-Catenin Nuclear Translocation.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the inhibitory effects of mitofusin 2 (MFN2) on hepatic stellate cell (HSC) activation and liver fibrosis progression in nonalcoholic fatty liver disease (NAFLD) through the inhibition of β-catenin nuclear translocation.
methodsIn vitro, primary mouse HSCs were treated with palmitic acid (PA), and MFN2 expression was modulated using lentiviral overexpression or knockdown. Fibrotic markers and β-catenin localization were analyzed via Western blot, cellular fractionation, and immunofluorescence. In vivo, liver fibrosis was induced in C57BL/6 J mice using a high-fat diet (HFD) combined with CCl₄ injections. MFN2 was systemically overexpressed or silenced via AAV2 vectors delivered through tail vein injection. Liver tissues were examined histologically and biochemically for fibrosis progression.
resultsPA treatment markedly downregulated MFN2 and upregulated fibrotic markers in HSCs. Overexpression of MFN2 strongly suppressed HSC activation, reduced α-SMA and N-cadherin levels, and significantly inhibited β-catenin nuclear accumulation. Conversely, MFN2 knockdown exacerbated fibrotic responses and promoted β-catenin translocation. In mice, MFN2 overexpression substantially attenuated collagen deposition and improved liver histology, while MFN2 silencing significantly aggravated fibrosis and enhanced β-catenin signaling.
conclusionMFN2 inhibits HSC activation and liver fibrosis by suppressing β-catenin nuclear translocation, making it a promising therapeutic target for NAFLD-related fibrosis and associated complications, such as hepatocellular carcinoma.
Indexed as
Identifiers
41661436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.